The United Kingdom’s National Institute for Health and Care Excellence (NICE) has issued a medical technology guidance recommending Thopaz+ (Medela AG Switzerland) for managing chest drains. NICE concluded: "The case for adopting Thopaz+ for managing chest drains is supported by the evidence. Thopaz+ can reduce drainage time and length of stay in hospital, and improves safety for people with chest drains. Its use may also improve clinical decision-making through continuous, objective monitoring of air leaks and fluid loss."
• In multiple clinical trials patients with the Thopaz+ chest drainage system have had shorter chest tube placements and also shorter hospital stays than patients with conventional chest drains.
• The NICE resource impact assessment shows that, at a national level, adopting Thopaz+ is expected to save around £8.5 million per year in England.
Read more: https://www.medela.com/healthcare/products/cardiothoracic-drainage/thopaz-plus